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DNA replication timing is known to facilitate the establishment of the epigenome, however,
the intimate connection between replication timing and changes to the genome and epi-
genome in cancer remain largely uncharacterised. Here, we perform Repli-Seq and integrated
epigenome analyses and demonstrate that genomic regions that undergo long-range epi-
genetic deregulation in prostate cancer also show concordant differences in replication
timing. A subset of altered replication timing domains are conserved across cancers from
different tissue origins. Notably, late-replicating regions in cancer cells display a loss of
DNA methylation, and a switch in heterochromatin features from H3K9me3-marked con-
stitutive to H3K27me3-marked facultative heterochromatin. Finally, analysis of 214 prostate
and 35 breast cancer genomes reveal that late-replicating regions are prone to cis and early-
replication to trans chromosomal rearrangements. Together, our data suggests that the
nature of chromosomal rearrangement in cancer is related to the spatial and temporal
positioning and altered epigenetic states of early-replicating compared to late-replicating loci.
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Replication of the mammalian genome is an essential processthat guarantees the accurate copying of genetic informationbefore cell division. Each round of replication represents an
opportunity for error, leading to the acquisition of mutations1
and copy number aberrations2–4. Epigenetic maintenance factors
are also associated with the DNA replication machinery5 and
therefore DNA replication represents a similar opportunity for
deregulation of the epigenome. The DNA replication timing
program of the cell is highly organised and defined as the tem-
poral sequence of locus replication events that occur during the
synthesis phase (S-phase) of the cell cycle, from early to late6,7.
Replication timing has been shown to stratify many features of
the genome and epigenome, including gene density, gene tran-
scription, histone modifications, DNA methylation and three-
dimensional (3D) chromatin organisation8–13. Generally, active
and open euchromatin regions are replicated early in S-phase,
and repressed and closed heterochromatin regions are replicated
late in S-phase7. Studies of mouse embryonic stem cell differ-
entiation show that re-organisation of the replication timing
program is accompanied by a concomitant re-organisation of the
epigenome across large domains14,15. As the replication timing
program contributes to both epigenetic maintenance and cell
identity, disruption of these processes could be a key cellular
event that also contributes to carcinogenesis. However, the rela-
tionship between replication timing and epigenome alterations in
cancer, and the combined impact on shaping the genomic land-
scape of tumour cells has remained largely unexplored.
We and others have previously shown that epigenetic dereg-
ulation in cancer can span large domains of long-range epigenetic
silencing (LRES) and activation (LREA) with coordinated gene
expression, histone modification, DNA methylation changes and
disruption of topologically associated domains (TADs) over
several kilobases to megabases16–18. Ryba et al. (2012) also
reported that up to 18% of the genome can change in replication
timing in acute lymphoblastic leukaemia19. Therefore, given the
long-range domain level of epigenetic change observed in cancer,
we were motivated to ask what is the relationship between
replication timing and associated alterations to the epigenome
and genome in cancer.
Here, we use high-resolution epigenome and genome-wide
characterisation of normal and cancer cells to investigate how the
replication timing landscape is associated with the cancer-specific
epigenome changes and chromosomal rearrangements observed
in prostate and breast cancers. We find that the differences in
epigenetic deregulation between early and late replication
underpin long-range epigenetic deregulation and potentially
shape the nature of cancer mutational landscape.
Results
Replication timing is largely conserved in cancer cells. To
determine if there are changes in replication timing in normal and
cancer prostate cells, we performed Repli-Seq6,20 in duplicate in
normal prostate cells (PrEC) and prostate cancer (LNCaP) cells
(see Methods, Supplementary Figure 1a–f). To examine the nature
of the replication timing landscape, we plotted the replication
timing weighted average (WA) values for all ~2.8 million mappable
1 kb bins (‘loci’) (Supplementary Figure 1g) and found that 94.3%
of loci are remarkably conserved in the cancer cells, using a strin-
gent WA difference of 25 (|ΔWA| < 25) (Supplementary Figure 1h).
In fact, only 5.7% of the genome showed a difference in replication
timing; 3.2% of the genome replicated later in LNCaP compared
to PrEC (ΔWA<−25), and 2.5% replicated earlier in LNCaP
compared to PrEC (ΔWA> 25) (Supplementary Figure 1g). To
identify domains of consecutive loci where the time of replication is
altered, we merged all loci within 50 kb that had a |ΔWA| > 25, and
found 314 domains replicated later and 244 domains replicated
earlier in LNCaP compared to PrEC. The later and earlier domains
are distributed across the genome spanning all chromosomes
(visualised in Supplementary Figure 2). Exemplary domains that
replicate later and earlier in the cancer cells are also shown in
Fig. 1a.
Differences in heterochromatin occur in late-replication. To
next investigate where replication timing stratifies the epigenome
and transcriptome, we examined gene expression and chromatin
differences between PrEC and LNCaP at early- and at late-
replicating loci. Similar to previous reports in other cell types6,11,
both prostate normal and cancer cells display high gene density
and high expression in early-replicating loci, and low gene density
and constitutively low gene expression in late-replicating loci
(Supplementary Figure 3a, b). The prostate cells also display
positive associations6,21 between early-replication and active
chromatin marks, and late-replication and repressive chromatin
marks (Supplementary Figure 3c). Moreover, we find that the
distribution of active and permissive marks, including H3K4me3,
H3K27ac, H3K4me1, H2AZac and H3K36me3 and DNAse1
hypersensitivity (HS), are progressively enriched towards
early-replicating loci, whereas the repressive marks, H3K9me3,
lamin A/C and lamin B1, are progressively enriched towards late-
replicating loci (Fig. 1b, Supplementary Figure 4a, b). Similar
chromatin and replication timing associations were identified in
normal breast epithelial cell line (HMEC) and breast cancer cell
line (MCF7) (Fig. 1c, Supplementary Figure 3d, Supplementary
Figure 4c).
Notably, only two of the chromatin marks, H3K27me3 and
H3K9me3, show different distributions across replication timing
between the normal and cancer cells. First, H3K27me3 is more
enriched in early-replicating loci than in late-replicating loci in
PrEC, whereas in LNCaP cells, H3K27me3 is more enriched in
late-replicating loci than early (Fig. 1b). Second, H3K9me3 is
enriched in late-replicating loci compared to early-replicating loci
in normal PrEC, whereas, in the cancer cells H3K9me3
enrichment is substantially reduced in late timing (Fig. 1b).
Opposing H3K27me3 and H3K9me3 enrichment at late-
replicating loci is also seen between HMEC and MCF7 (Fig. 1c).
Both H3K27me3 and H3K9me3 remodelling has been reported to
occur in cancer22,23, but an inverse relationship has not
previously been associated with replication timing.
Next, we investigated whether the chromatin state is also
altered in cancer cells within the regions that change in
replication timing. Generally, we find that LNCaP cells show a
gain of permissive marks at earlier replicating loci and loss of
permissive marks at later replicating loci (Supplementary
Figure 4d). Conversely, we find a loss of repressive marks in
earlier replicating loci and a gain of repressive marks in later
replicating loci (Supplementary Figure 4e). Interestingly,
H3K27me3 does not show the same trend of reciprocal
association as other repressive marks, but in contrast only shows
enrichment towards later loci in LNCaP compared to PrEC
(Supplementary Figure 4e). Therefore, genome-wide remodelling
of H3K27me3 appears to specifically occur at loci that replicate
later in cancer cells as well as regions of constitutive late-
replication.
Replication timing states stratify methylation alterations. To
investigate the relationship between replication timing and DNA
methylation, we performed whole genome bisulfite sequencing
(WGBS) in prostate and breast normal and cancer cell lines and
clinical samples. We find that for normal prostate and breast cells
(PrEC and HMEC), late-replicating loci are less methylated
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compared to early-replicating loci (Fig. 2a, Supplementary Fig-
ure 5a), similar to other cell types12,13,24. Notably, there is an even
greater loss of DNA methylation at late-replicating loci in cancer
cells (LNCaP and MCF7) relative to normal cells (Fig. 2a, Sup-
plementary Figure 5a). Furthermore, we observe similar trends in
the preferential loss of methylation at late-replication loci relative
to early loci in clinical prostate and breast cancer WGBS datasets
(Supplementary Figure 5b, c).
Moreover on a broad scale, methylation is reduced in LNCaP
compared to PrEC at regions of constitutive late replication
(Fig. 2b, Supplementary Figure 6a). However, unlike in PrEC
where the DNA methylation and replication timing profiles are
largely distinct, the genome-wide DNA methylation profile is
more in synchrony with the replication timing profile in LNCaP
cells (Fig. 2b, Supplementary Figure 6a). Furthermore, we find
more hypomethylated (LNCaP− PrEC, ΔmCG <−0.2) than
hypermethylated (LNCaP− PrEC, ΔmCG > 0.2) loci genome-
wide (Fig. 2c), and hypomethylation is significantly more
enriched in late-replicating loci compared to early-replicating
loci (74% vs. 28%, test of equal proportions p < 2.2e−16).
Conversely, hypermethylation is significantly enriched in early-
replicating loci compared to late-replicating loci (17% vs. 2%, test
of equal proportions p < 2.2e−16) (Fig. 2c). Notably, hypomethy-
lated loci in cancer cells are primarily enriched for intergenic
regions, whereas hypermethylated loci are enriched for CpG-
islands, CpG-island shores and promoter/5′ UTR regions
(Fig. 2d). We further observe the association of partially
methylated domains (PMDs) and lamina-associated domains
(LADs) with the hypomethylated loci, and disassociation with
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Fig. 1 Relationship between chromatin and replication timing in normal and cancer. a Representative examples of regions of timing change between PrEC
and LNCaP. PNDVs for PrEC (green) and LNCaP (red) are shown in the upper panels. The summarised WA values for each replicate are beneath. Regions
that replicate later in LNCaP (ΔWA<−25) are highlighted in pink. Regions that replicate earlier in LNCaP (ΔWA> 25) are highlighted in blue. Scale bars
represent 1 Mb. b Percentage occupancy of chromatin marks for 1 kb loci (WA blocks) within replication timing percentiles for repressive marks H3K27me3
and H3K9me3 in PrEC and LNCaP. c Percentage occupancy of chromatin marks for 1 kb loci (WA blocks) within replication timing percentiles for repressive
marks H3K27me3 and H3K9me3 in HMEC and MCF7
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data shows that cancer-associated DNA hypermethylation occurs
preferentially in early-replication at CpG-islands and hypomethy-
lation in late-replication at intergenic regions.
Alterations in replication timing modulate gene expression.
We next investigated if alterations in replication timing in cancer
are associated with gene expression. Using the definition of
|ΔWA| > 25, we find that more genes are replicating later (515)
than genes that are replicating earlier (169) in LNCaP compared
to PrEC (Fig. 3a). Genes that replicate earlier in LNCaP are sig-
nificantly increased in expression, whereas the genes that replicate
later are significantly repressed (Fig. 3a). We performed gene set
enrichment analysis (GSEA) and observe no enrichment for
earlier upregulated genes (Supplementary Figure 7). In contrast,
genes that replicate later and are downregulated are enriched in
terms related to cancer such as EMT, TNFα signalling, KRAS
signalling, cell movement and cell proliferation (Supplementary
Figure 7, Supplementary Table 1). Later genes in the cancer cells
are also significantly enriched for tumour suppressor genes25 (test
of equal proportions, p= 2.283e−06), whereas the genes repli-
cating earlier are not (test of equal proportions, p= 0.2854).
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Fig. 2 Replication timing correlates with DNA methylation in cancer. a DNA methylation (WGBS) density distributions for early (blue) and late (red) loci
per cell line. Adjacent are scatterplots of DNA methylation in relation to replication timing (WA) for all measured 1 kb loci in PrEC and LNCaP. Blue dashed
line indicates early (WA > 75) and red dashed line indicates late (WA< 20). b Representative examples of late-replicating regions common to both PrEC
and LNCaP (shaded) that become hypomethylated in LNCaP. The correlation between DNA methylation and replication timing values increases from PrEC
(Spearman’s 0.3073, p < 2.2e−16) to LNCaP (Spearman’s 0.4985, p < 2.2e−16). Scale bar represents 5Mb. c Percentage (y-axis) of PrEC early and late
regions (1 kb loci) that are hypermethylated (LNCaP-PrEC, ΔWGBS > 0.2) and hypomethylated (LNCaP-PrEC, ΔWGBS <−0.2). Asterisks indicate
significantly different percentages between early and late (test of equal proportions, p < 2.2e−16). d Associations between genomic elements and hypo-
and hypermethylated 1 kb loci. Association is above zero, and disassociation is below zero. Asterisks indicate significant associations (FDR < 0.05, Fisher’s
exact test)
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LNCaP cells predominantly relates to suppression of genes within
cancer-related pathways in late replication.
To investigate if genes that show replication timing changes
in cancer are also accompanied by chromatin remodelling,
we compared the alteration in replication timing status to the
enrichment of H3K27me3 and H3K4me3 at gene promoters
(Fig. 3b, c). We find that genes that change to earlier replication
timing are associated with a more active promoter environment,
characterised by concordant enrichment of H3K4me3 and
depletion of H3K27me3. Similarly, we find that genes that
change to later replication timing are associated with a more
repressive promoter environment, characterised by concordant
depletion of H3K4me3 and enrichment of H3K27me3.
We next asked if gene promoters that are located within
regions of altered replication timing in cancer also display a
change in DNA methylation. Interestingly, we find distinct
hypermethylation at promoter CpG-islands in cancer, regardless
of the direction of replication timing change (Fig. 3d). However, a
higher proportion of CpG-island promoters become hypermethy-
lated in genes that change to a later replication timing (n= 52,
18%) relative to hypermethylated CpG-island promoters that
change to an earlier replication timing (n= 12, 11%). Moreover,
the genes that are hypermethylated and replicate earlier in
LNCaP tend towards increased expression (Fig. 3e) and in
contrast, genes that are hypermethylated and replicate later
in LNCaP tend towards decreased expression (Fig. 3f). Together
this data suggests that a change in replication timing is also
associated with a concerted change in both gene expression and
the epigenetic status of the promoter.
Epigenetic alterations occur concordantly in the same LADs.
Association with the nuclear periphery (nuclear lamina) is known
to be a characteristic of late replication timing6,9,26, however, it is
less clear how differences in nuclear lamina association between
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Fig. 3 Relationship between replication timing, DNA methylation and expression. a Difference in replication timing (ΔWA) compared to the change in gene
expression (log fold change, logFC). b, c Scatterplots showing the relationship between change in replication timing and change in H3K27me3 and
H3K4me3 read density between PrEC and LNCaP at gene promoters. In a–c, dashed lines indicate a |ΔWA| > 25, outside of which indicates a change in
replication timing (red points). logFC boxplots for later or earlier genes are on the left and the right of the scatterplot, respectively. Later or earlier genes are
significantly changed in expression compared to genes between |ΔWA| > 25 (asterisk, Student’s T-test, p < 2.2e−16). d Difference in replication timing
compared to change in methylation at CpG-island promoters. Vertical dashed lines indicate a |ΔWA| > 25 (LNCaP-PrEC) and horizontal dashed lines
indicate a |ΔWGBS| > 0.2 (LNCaP-PrEC). Promoters that are hypermethylated and either later or earlier are coloured in pink. e Comparison of expression
levels (square root mean.TPM) between PrEC and LNCaP for hypermethylated and later gene promoters. f Comparison of expression levels (square root
mean.TPM) between PrEC and LNCaP for hypermethylated and earlier gene promoters. Solid diagonal line indicates equal expression between PrEC and
LNCaP; those above the line are more expressed in LNCaP and those below the line are less expressed in LNCaP. Interestingly, the hypermethylated earlier
replicating genes that display increased expression belong to two previously described groups of CpG-island promoter hypermethylation17 where either,
hypermethylation was associated with alternative promoter usage (FRY, MCCC2 and CCDC67, red circles) or, hypermethylation of the CpG-island borders
resulted in augmentation of expression in prostate cancer (NCAM and IQGAP2, blue circles). For boxplots, centerline indicates the median, box limits
indicate upper and lower quartiles, whiskers indicate the 1.5 interquartile range and points indicate outliers
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replication timing. To address this question, we performed ChIP-
seq of both lamin A/C and lamin B1 in PrEC and LNCaP. Spe-
cifically, we find that late replication timing is characterised by
the presence of both lamin A/C and lamin B1 LADs rather than
A/C or B1 alone (Fig. 4a), and LADs that are maintained between
normal and cancer show consistent late replication timing
(Supplementary Figure 8a). In contrast, LADs that are either ‘lost’
or ‘gained’ in the cancer cells show a change in their replication
timing program to earlier or later replication, respectively
(Supplementary Figure 8a). We were therefore interested to
examine if a change in LAD boundaries between normal and
cancer also relates to a change in replication timing. We plotted a
heatmap of WA values over the boundaries of PrEC LADs that
are shifted in LNCaP (as shown by the white curve) (Fig. 4b). We
found a remarkable correlation between the borders of LADs and
the transition from early replication timing outside the LAD to
late replication timing within the LAD. Moreover, a shift in the
LAD boundary in LNCaP, compared to PrEC, correlates with the
AVPR1B IL10 CD55 CD34 MIR205HG SERTAD4 KCNH1 RD3 INTS7 ATF3
RefSeq genes
LRES
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shift where replication timing transitions from early to late, and
ultimately where timing is different between the normal and
cancer cell (Fig. 4b).
Since we observed differences in both DNA methylation and
repressive histone modifications between LNCaP and PrEC in
late replication, we next asked whether these epigenetic
differences are also located at nuclear lamina and co-occur at
the same loci. Previous reports have shown that DNA
hypomethylation in cancer occurs in large domains that
correspond to LADs or large domains of heterochromatin27,28.
Therefore, to determine if there is a combinatorial relationship,
we called broad domains of H3K27me3 and H3K9me3 and
annotated the 1 kb replication timing loci for differences in the
presence of histone domains, LADs and hypomethylated
differentially methylated regions (DMRs) and tabulated the
combinations (Supplementary Figure 8b). We find that the
predominant pattern of chromatin differences at late-replicating
regions in both PrEC and LNCaP is maintenance of lamina
association but concomitant DNA hypomethylation, H3K27me3
enrichment, and either H3K9me3 depletion (Rank 1; 17.40%,
Supplementary Figure 8b, example Fig. 4c) or H3K9me3 absence
(Rank 2; 15.92%, Supplementary Figure 8c). The next most
common pattern shows the acquisition of lamina association in
LNCaP, a change to later replication and hypomethylation
across the new LAD (Rank 3; 6.9%, Supplementary Figure 8b,
example Fig. 4d). GSEA of the genes within these regions
(Supplementary Figure 8d) indicates that Rank 1 genes are
enriched in cell–cell adhesion, cell–cell junction, and adhesion
molecules; Rank 2 genes in cell–cell adhesion and Rank 3 genes in
neuron migration and glial cell differentiation. We find similar
combinatorial histone and methylation alterations at late-
replicating loci when comparing an 18-state chromHMM model
(Supplementary Figure 9); the most frequent change (state 9 to 7
between PrEC and LNCaP; 15.3%) is also DNA hypomethylation,
H3K9me3 loss and concordant H3K27me3 gain at late-
replicating LADs (Supplementary Figure 9c, 1st row). Together,
these data show that hypomethylation and heterochromatin
alterations in cancer are occurring concordantly within the same
late-replicating LADs.
LRES and LREA domains have altered replication timing
states. We previously identified long-range epigenetically acti-
vated LREA (n= 35)17 and silenced LRES domains (n= 47)18 in
prostate cancer cells by identifying coordinated changes in gene
expression and histone marks. We now ask whether LRES and
LREA domains are also associated with alterations in replication
timing. Compared to a random distribution of similarly sized
regions, we find LREA domains are significantly distributed
towards earlier replication and conversely, LRES domains are
significantly distributed towards later replication in the cancer
cells (Fig. 4e). Further, LRES regions more often overlap later
domains than randomised regions (binomial test, p= 0.038), and
similarly LREA regions more often overlap earlier domains
(binomial test, p= 0.00097). Exemplary LREA regions that
replicate earlier in LNCaP compared to PrEC, forming ectopic
replication initiation zones, are shown (Fig. 4f, Supplementary
Figure 10). Conversely, exemplary LRES regions that replicate
later in LNCaP, potentially due to loss of replication initiation
zones, are shown (Fig. 4g, Supplementary Figure 10). Together
our data suggests that long-range domains of transcriptional
alterations in cancer are also associated with concordant altera-
tions in replication timing.
Conservation of replication timing alterations. We next asked
whether there are associated patterns of replication timing
alterations in other cancer cell types. We performed principal
component analysis (PCA) and hierarchical clustering using
PrEC, LNCaP and publicly available ENCODE Repli-Seq
datasets6,29, that includes five cancer cell lines Hela S3, MCF7,
SK-N-SH, HepG2 and K562, normal cultured primary cells,
established fibroblast cell lines, Epstein–Barr Virus (EBV) trans-
formed normal lymphoblastoid cells and embryonic stem cell
(ESC) (Fig. 5a). In both PCA and hierarchical clustering, cell
types were divided into three major clusters (Fig. 5a, b). The
normal cells are clustered together, containing the normal epi-
thelial (PrEC), epidermal and endothelial cells, as well as the
fibroblasts. The normal cells are separate from the clusters con-
taining the EBV transformed normal lymphoblasts and cancer
cell lines. The closer clustering of EBV transformed normal
lymphoblasts to cancer cell lines suggest the transformation
process has made these cells more cancer-like. Notably, all the
cancer cell lines cluster together with the exception of Hela S3.
The ESC line was also found to associate with the cancer cells,
potentially suggesting a progenitor-like state of cancer. Interest-
ingly, most cancer cells assayed cluster separately to normal cells
regardless of cell of origin, whereas, RNA-seq data less clearly
separates normal from cancer cells (Supplementary Figure 11).
To interrogate if there are replication timing domains that are
conserved across cancer types, we identified regions that
displayed consistent differences in replication timing domains
in the cancer datasets compared to all other non-cancer datasets.
We identified 16 earlier cancer domains (ECDs) and 56 later
cancer domains (LCDs). Representative examples of ECDs and
LCDs across multiple cancer types are shown in Fig. 5c.
Fig. 4 Long-range epigenetically regulated domains have altered replication timing. a Average plots of PrEC and LNCaP WA values over domains of lamin
A/C-only, lamin B1-only or both. For both PrEC and LNCaP, LADs containing both lamin A/C and B1 are later than lamin A/C-only LADs (asterisk, p < 2.2e
−16) and lamin B1-only LADs (asterisk, p < 2.2e−16). One-tailed Mann–Whitney–Wilcoxon tests were performed for the alternative that LADs containing
both lamin A/C and B1 is ‘less’. Plots show an average line with width of shading indicating confidence intervals. b Heatmap of PrEC and LNCaP WA
values over the boundary of PrEC LADs, ordered by degree of LAD extension (upstream of 5′ and downstream of 3′) and contraction (between 5′ and 3′)
in LNCaP. The LADs used here contain both lamin A/C and lamin B1. Black lines down the centre of heatmaps represent PrEC LAD boundaries. White
lines indicate the LAD boundary in LNCaP. Scale for WA is from late (red) to early (blue). Extension of the LAD boundary in LNCaP (upstream of
PrEC 5′ and downstream of PrEC 3′) corresponds to these regions being significantly later replicating in LNCaP than PrEC (p < 2.2e−16, one-tailed
Mann–Whitney–Wilcoxon test). Reciprocally, contraction of the LAD boundary in LNCaP (downstream of PrEC 5′ and upstream of PrEC 3′) corresponds to
these regions being significantly earlier replicating in LNCaP than PrEC (p < 2.2e−16, one-tailed Mann–Whitney–Wilcoxon test). c Representative example
of a late-replicating region in LNCaP showing maintained LADs with coordinate DNA hypomethylation, H3K27me3 gain and H3K9me3 loss (Rank 1,
Supplementary Figure 8b). Scale bar represents 1Mb. d Representative example of a late-replicating region in LNCaP showing coordinate LAD gain, DNA
hypomethylation and H3K27me3 gain (Rank 3, Supplementary Figure 8b). Scale bar represents 1Mb. e The average replication time of each LREA or LRES
region is compared to a distribution of 1000 randomised LREA or LRES regions (boxplot). The significance of difference in WA distributions between
regions and random is indicated (Mann–Whitney–Wilcoxon test). f, g Representative examples of overlaps between LRES and LREA, and domains of
replication timing (earlier, later). Scale bar represents 1 Mb
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Interestingly, the majority of ECDs (15/16) and LCDs (55/56)
overlap regions with apparent high replication timing variation,
suggesting that these loci are innately malleable, yet notably
distinct in timing in cancer compared to other cell types
(Supplementary Figure 12). Genes within ECDs and LCDs
(Supplementary Table 2) include cancer-related genes such as
ETS1, FOXP2 and BAMBI. Notably, 46.88% of ECD and 47.37%
of LCD genes have ‘lincRNA’ status based on GENCODE 19 with
LCD genes being significantly enriched in lincRNAs (test of equal
proportion, p= 0.00001128). To determine if there is potential
coordinate gene function, we relaxed our domain calling cutoff
(see Methods) and looked for enrichment of GSEA terms. The
analyses suggest that ECD genes may play a role in cell-to-cell
adhesion and LCD genes may play a role in the cell’s immune
response (Supplementary Figure 13).
Replication timing states stratify genomic rearrangements. It
has been previously reported that DNA hypomethylation, het-
erochromatin remodelling and late replication timing each
separately predispose the genome to chromosomal instability in
tumourigenesis1,30,31. Therefore, to investigate if replication
timing potentially influences the nature of chromosomal rear-
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Fig. 5 Conservation of replication timing alterations in cancer. WA values of all publically available Repli-Seq datasets, including PrEC and LNCaP, are
assessed using PCA (a) and hierarchical clustering (Ward’s criterion) (b). All clusters have a clusterwise Jaccard bootstrap mean above 0.8 indicating their
stability; means are 0.9399 (cluster 1), 0.8676 (cluster 2) and 0.8225 (cluster 3). Samples are identifiable by colour and number key. c Shown are
representative examples of loci that are earlier cancer domains (ECDs) or later cancer domains (LCD) in multiple cancers compared to other cell types.
Shaded boxes indicate ECDs or LCDs with logFC≥ 1. Scale bar represents 1 Mb
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publicly available clinical datasets32–35. We find in all prostate
datasets that genomic rearrangement breakpoints are enriched in
late-replicating DNA (WA < 20) and deplete in early-replicating
DNA (WA > 75) in PrEC (Fig. 6a). Chromosomal rearrange-
ments were further classified as cis or trans depending on whether
they were inter- or intra-chromosomal. We find that trans
translocations are enriched at early-replicating loci in PrEC and
cis rearrangements at late-replicating loci in PrEC in the Baca and
Berger datasets (Fig. 6b, c). We further divided the cis rearran-
gements into discrete subtypes and found inversions, deletions
and long-range insertions were all enriched in late replication
(Supplementary Figure 14a). To further support this finding, we
used published breast cancer WGS structural variation data from
Yang et al.35 with MCF7 replication timing data. We also observe
the same trend where trans variants are enriched in early-
replicating loci and cis variants are enriched in late-replicating
loci (Fig. 6d, e).
We further investigated the nature of gene fusions that are
commonly found in prostate cancer and asked if the genes
were located in regions that displayed differences in replication
timing. We examined replication timing states in PrEC and
LNCaP of all the gene fusions documented in the Robinson
dataset32. Interestingly, we found that the majority of the
breakpoints occurred in regions that shared the same state of
replication timing (Supplementary Figure 14b). Supplementary
Dataset 1 summarises all the breakpoints in prostate cancer
including those that show significant replication timing differ-
ences. Of all gene fusions assayed, TMPRSS2-ERG located on
chromosome 21q22.2 was the most common (209/4122) fusion
found in patients. Strikingly, in 195/209 fusion events, the 3′ ERG
translocation points were located in a domain that changes
replication timing from early to late S-phase in LNCaP
(Supplementary Figure 14b). Supplementary Figure 14c shows
the domain of replication timing change that harbors the ERG
locus. Taken together our data shows that the replication timing
status of a locus is associated with increased susceptibility to
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Fig. 6 Replication timing stratifies the nature of chromosomal rearrangements. a Enrichment of rearrangement breakpoints for early or late replication in
PrEC using public datasets32–34. b Replication timing (PrEC WA) distributions for trans (purple) and cis (orange) rearrangement breakpoints. Solid lines are
distributions for Baca et al.33 data and dashed lines are distributions for Berger et al.34. Vertical red and blue dotted lines indicate late (WA < 20) or early
(WA > 75) cutoffs. c Enrichment of rearrangement breakpoints for early or late replication separated by cis or trans status. d Enrichment of rearrangement
breakpoints all together or separated by cis or trans status for early or late replication in MCF7 using public dataset35. e Replication timing (MCF7 WA)
distributions for trans (purple) and cis (orange) rearrangement breakpoints. Vertical red and blue dotted lines indicate late (WA < 17) or early (WA > 73)
cutoffs. For a, c and d, asterisks indicate significant enrichment (FDR < 0.05, Fisher’s exact test)
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Discussion
The major focus of this study was to address whether there are
replication timing differences in cancer and if so, to investigate
what was the association between replication timing and altera-
tions to the cancer epigenome and genome. Here, we make the
noteworthy discovery that replication timing and the opposing
remodelling of the epigenome, in early vs. late replication, is
associated with the mode of chromosomal rearrangements in
cancer. We demonstrate that genomic regions that undergo long-
range epigenetic deregulation in cancer also show concordant
differences in replication timing. Notably, late-replicating
regions in prostate and breast cancer cells display a remarkable
reduction of DNA methylation, and a switch in heterochromatin
features from H3K9me3-marked constitutive to H3K27me3-
marked facultative heterochromatin. Our data support a model
where alterations in epigenetic remodelling in cancer cells in early
and late replicating loci provide increased probability for cis or
trans chromosomal rearrangements based on the nuclear spatial
context.
The replication timing program is known to be re-organised
during cellular differentiation and reflects cellular
identity11,14,15,21. Therefore, it was interesting to find that the
replication timing profiles between different cancer cell types are
more similar to each other than to non-cancer cells, suggesting
that there may be shared domains that commonly display
alterations in replication timing in tumourigenesis. These shared
domains may have potential functional relevance to cancer, as
we find enrichment of genes involved in cancer-related pathways,
such as cell-to-cell adhesion and immunological signatures,
and also enrichment in genes with lincRNA status raising the
possibility of important regulatory functions that are potentially
altered in cancer36.
It has previously been proposed that replication timing
represents a higher-order functional unit9,29, however our data
now suggests that timing is also a unit for epigenomic dereg-
ulation during tumourigenesis. We find transcriptional and epi-
genetic alterations within altered replication timing regions
between normal and cancer cells. We further find that domains of
replication timing alterations in prostate cancer cells correlate
with previously observed domains of long-range transcriptional
and epigenetic remodelling for both LRES18 and LREA17 regions,
whereby earlier domains become more active and later domains
become more repressive. This directional relationship between
replication timing and gene expression has been observed in
development and differentiation11,14,15. For example in human
cell lines, Rivera-Mulia et al.11 report that developmental shifts to
later timing precedes transcriptional down-regulation and
developmental shifts to earlier timing follows transcriptional up-
regulation for the majority of replication timing switching genes,
suggesting that replication timing may be both a driver and a
passenger of transcription. In our study, we find that later
replicating genes are primarily down-regulated, and show cancer-
related gene ontology. We therefore speculate that a change to
later timing in tumourigenesis potentially precedes down-
regulation of these cancer-associated genes. Whilst previous
studies37,38 have shown that replication timing can impose par-
ticular chromatin states, more work is required to establish
whether epigenetic changes come first and are prior too or occur
as a result of a change in replication timing in cancer.
There has been no integrative study between replication timing
and epigenomic changes in normal and cancer cells in the same
cell system. Pairwise associations between replication timing and
epigenetic features have been observed during mouse ES cell
differentiation or between mostly disjoint normal human cell
lines from different tissue origins12,13,26–28,39. Here, using an
integrative approach we now identify that the most widespread
combinatorial epigenomic alteration between normal and pros-
tate cancer cells is DNA hypomethylation, accompanied with
a switch from H3K9me3-constitutive to H3K27me3-facultative
heterochromatin within lamina-bound late-replicating regions.
H3K27me3 and DNA methylation are generally antagonistic and
commonly switch in cancer cells28,40 and DNA hypomethylation
in mouse embryonic fibroblasts leads to redistribution of
H3K27me341, suggesting a direct relationship between loss of
DNA methylation and gain of H3K27me3. H3K9me3 loss may
also directly contribute to DNA hypomethylation, as H3K9me3
is required to enhance the activity of UHRF1 and consequently
DNMT142,43. Our findings suggest that there is a highly co-
ordinated alteration of the cancer epigenome that occurs exqui-
sitely in genomic regions that replicate late in S-phase.
Finally, we observe an association between chromosomal
rearrangements and replication timing, with late-replicat-
ing regions prone to cis rearrangements and early-regions to trans
rearrangements in both breast and prostate cancer. Previous
studies1,44–46 have reported associations of chromosomal rear-
rangements with both early and late replication, but not in rela-
tion to the altered state of the epigenome. Of note, Morganella
et al.46 identified all breast cancer rearrangements to be associated
with early replication timing, whereas, De et al.1 identified that
large deletions are enriched for late replication while large
amplifications are enriched for early replication. These reports are
in contrast to our study where we find a clear bias towards late
replication for most rearrangements other than translocations.
The differences could be due to differential DNA repair pathway
usage between early and late regions of the nucleus47,48 and the
repair pathways active within the different cancer types.
Our combinatorial epigenome and replication timing data
leads us to propose a model to explain how replication timing
status and associated epigenetic alterations may influence the
nature of chromosomal cancer rearrangements (Fig. 7). Hypo-
methylation and loss of H3K9 methyltransferases have been
separately linked to increased genomic instability in cancer30,31.
However, our data shows that late-replicating loci in cancer are
both hypomethylated and switched from a H3K9me3-marked
constitutive heterochromatin state to a H3K27me3-marked
facultative heterochromatin state. We suggest that it is the com-
bination of epigenetic remodelling in the context of the replica-
tion timing state that is associated with increased chromosomal
rearrangements. In particular, we hypothesise that the switch to
facultative heterochromatin may sensitise late-replicating regions
to DNA damage and/or error-prone repair. Previous 3D studies
suggest that the chance of a translocation occurring is propor-
tional to the degree of chromatin interaction between two loci
and interactions occur more frequently between loci within the
same chromosome territory or between adjacent territories than
between distant territories49–51. Interphase chromosomes are
organised such that early-replicating loci are located towards the
nuclear centre and late-replicating loci are located towards the
nuclear periphery (lamina-bound) (Fig. 7)9,21,26. We therefore
propose that bias towards cis or trans chromosomal rearrange-
ment is related to the spatial and temporal positioning of early-
replicating compared to late-replicating loci. As late-replicating
loci are more self-contained52, we suggest that DNA breaks are
more likely to involve cis rearrangements. In contrast as early-
replicating loci are more interactive52,53, DNA breaks occurring
in regions replicating in early S-phase are more likely to result in
trans translocations.
Our model is also supported by studies that show copy number
aberration breakpoints generally have the same replication timing
and interact long-range1, and that translocation partners are
required to be within the same spatial area, transcription54 or
replication factory55, before translocation can occur. A pertinent
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example for prostate cancer is the TMPRSS2-ERG gene fusion
that occurs in ~50–80% of all prostate cancer56. Studies show
that nuclear spatial proximity between TMPRSS2 and ERG is a
determining factor of fusion frequency57. Furthermore, spatial
proximity can be induced through activation of the genes by the
androgen receptor (AR) under testosterone (DHT) treatment,
which works to increase spatial proximity by targeting TMPRSS2
and ERG to the same replication factory55,57. In conclusion, our
combinatorial data analysis supports a paradigm where epigenetic
deregulation between early and late replication can modulate the
mutational landscape and underpin long-range epigenetic
deregulation of the cancer genome.
Methods
Cell culture. All cancer cell lines were purchased from ATCC (USA) and cultured
in our lab following standard protocols. LNCaP human prostate cancer cells
(ATCC #CRL-1740) were maintained in T-medium (Gibco, Formula no. 02-
0056DJ) supplemented with heat-inactivated foetal bovine serum (10%, Gibco,
16000-044), L-Glutamine (2 mM) (Gibco, #25030-081) and Penicillin/Streptomy-
cin (50 units/50 μg) (Gibco, #15070-063). MCF7 human breast cancer cells (ATCC
#HTB-22) were maintained in RPMI-1640-based medium containing 5% (v/v)
foetal bovine serum. PrEC normal human prostate epithelial cells (Cambrex Bio
Science, #CC-2555, tissue acquisition number 13683) were maintained in prostate
epithelial cell growth medium (PrEGM, Lonza, #CC-3165) supplemented with
SingleQuots growth supplements (Lonza, #CC-4177).
Repli-Seq data generation and processing. BrdU-labelled DNA was generated as
previously described6,20. Briefly, cells were labelled with BrdU (50 μM, Sigma,
#B5002) for 2 h. Labelled cells were sorted into 6 fractions across the cell cycle
(G1b, S1, S2, S3, S4, G2M) as per protocol on the FACS AriaII. DNA extraction
and BrdU-labelled DNA immunoprecipitation were performed with anti-BrdU
antibody (40 μL of 25 μg mL−1, BD Pharmingen, #555627). Validation of BrdU
immunoprecipitation was carried out using qPCR on known Early (BMP1) and
Late (DPPA2) loci (Supplementary Figure 1a, b, Supplementary Table 3). ssDNA
was reconstituted for the complementary DNA strand using Klenow extension with
random hexamers (Random Primers DNA Labeling System, Invitrogen #18187-
013) using 10 ng of ssDNA input and a 2 h incubation. Reconstituted dsDNA was
rechecked for enrichment of known early and late loci using qPCR (Supplementary
Figure 1c). Klenow-treated products were sonicated using a Sonifier 250 probe
sonicator. 15 μL of Klenow-treated dsDNA was sent to University of Southern
California Epigenome Centre Data Production Facility for 50 bp single-end
sequencing on the Illumina HiSeq 2000. The DNA amounts and full sequencing
details can be found in Supplementary Table 4.
Replication timing WA scores were calculated according to Hansen et al.6 with
slight modifications. Repli-Seq fractions were mapped to hg19 using bowtie58
(v1.1.0). To avoid bias from duplications or repeats, read densities were calculated
in 150 bp intervals and intervals were excluded from further analysis if they
contained greater than 20 reads per 150 bp window. Read densities were calculated
in 50 kb sliding windows at 1 kb intervals across the remaining genomic regions,
excluding chrY and chrM. Read densities were normalised to reads/counts per
million and 50 kb windows with low coverage (5 reads/counts per million) were
removed. To account for variation in sequencing coverage, mapability and cell-type
specific copy-number variations, the remaining 50 kb window reads/counts per
million values in all 6 fractions of a given sample were converted to a percentage of
total signal at each 1 kb locus called percent-normalised density values (PNDV)
(Supplementary Figure 1d). The PNDV value represents the percentage of
replication occurring within a particular timing fraction at a given 1 kb locus.
PNDV values were then converted into a single replication timing WA score per
1 kb loci using the following formula: weighted average= (0.917*G1)+ (0.750*S1)
+ (0.583*S2)+ (0.417*S3)+ (0.250*S4)+ (0*G2). The formula for this
transformation was obtained from the ENCODE method for ‘Replication Timing
by Repli-Seq’. WA values represent the time of replication, where a higher WA was
indicative of an earlier time of replication.
Repli-Seq was performed in duplicate for each cell line. Each sample was
processed independently up to and including calculation of the WA value. WA
values for replicates of LNCaP and PrEC are highly correlated (r2 values > 0.99)
(Supplementary Figure 1e). Duplicate WA values per cell line were then
averaged and used for downstream analysis. The distributions of WA scores
were comparable to the WA distributions in other normal and cancer cell Repli-Seq
datasets (Supplementary Figure 1f). Early- and late-replicating regions were
defined as those regions in the top and bottom 10% of WA scores in both cell
lines. This definition gives upper and lower limits of 75 and 20 respectively for
PrEC and LNCaP (i.e. early regions have WA > 75 and late regions WA < 20).
WA thresholds for a change in timing were defined by the following process:
differences in WA between replicates of the same cell line are representative of
random noise and therefore can be used as an empirical null distribution for the
hypothesis test that the WA difference between LNCaP and PrEC is equal to zero.
The maximum observed difference, in our data, between replicates is |ΔWA|= 23
(Supplementary Figure 1h). To be conservative, we chose a cut-off of |ΔWA| > 25
as a value that occurs infrequently (or never) by chance under the null.
Differences in WA that are larger than ±25 ΔWA are therefore considered to show
a robust change in replication timing. To identify domains of loci with changed
replication timing, we merged all loci within 50 kb that had |ΔWA| > 25. On
average, altered replication timing domains were ~295 kb wide. For MCF7, the














Fig. 7 Late replication timing is more sensitive to genetic and epigenetic damage. Replication timing is spatially organised within the nucleus.
Transcriptionally active early-replicating loci are often close in proximity with each other in transcriptional hubs towards the nuclear centre51,78,79.
Transcriptionally inactive late-replicating loci are typically heterochromatin, condensed and localised to the nuclear periphery and nuclear lamina51,78,79. In
prostate and breast cancer cells, early-replicating loci remain transcriptionally active, however, late-replicating loci switch from a methylated H3K9me3-
marked constitutive heterochromatin state to a hypomethylated H3K27me3-marked facultative heterochromatin state, and potentially more susceptible to
DNA damage and/or error-prone repair leading to an increase in chromosomal rearrangements. We speculate that if a DNA break occurs in late replication
it is more likely to be repaired in cis as late-replicating loci are more self-contained and located towards the nuclear periphery. In contrast, if a break occurs
in early replication, this is more likely to result in trans translocations, as there is increased potential for interchromosomal interactions within structures
like transcriptional hubs in the nuclear centre
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Whole genome bisulphite sequencing and processing. PrEC and LNCaP WGBS
libraries were prepared using the Illumina Paired-end DNA Sample Prep Kit
(discontinued, Illumina, CA, USA). Briefly, genomic DNA was extracted from cells
using QIAamp Mini Kit (QIAGEN, #51304). 1 μg of input DNA was spiked with
unmethylated lambda DNA (0.5%) (Promega, #D1521). DNA was sonicated to
produce DNA fragments of around 250 bp in length, end-repaired using the
Paired-End Sample Prep kit (Illumina #PE102-1001) and cleaned using QIAquick
PCR Purification kit (QIAGEN, #28104). A-tailing and adapter ligation were
performed according to the Illumina protocol. The adapter-ligated DNA was gel
size selected (260–330 bp) using Qiagen Gel extraction kit (Qiagen, #28704).
Bisulphite treatment was carried out as previously described59, with the bisulphite
reaction performed for 4 h at 55 °C. Converted libraries were enriched in five
independent PCR reactions for 10 cycles using PfuTurbo Cx Hotstart DNA
polymerase (Stratagene, #STG600410). The five independent reactions were pooled
and purified using the MinElute PCR Purification Kit (QIAGEN, #28004). Paired-
end 100 bp sequencing was performed for each library on the Illumina HiSeq 2500
platform. The MCF7 WGBS library was performed using the CEGX TrueMethyl
Whole-Genome kit (v2.1).
WGBS libraries were processed as previously described60 (see Supplementary
Methods). DMRs were called from PrEC and LNCaP WGBS data using the
package MethPipe61 (v3.4.2). PMDs were called from LNCaP WGBS data using
MethPipe.
RNA-seq data generation and processing. For PrEC and LNCaP, total RNA in
biological triplicates was spiked with external controls (ERCC RNA spike-in Mix,
Thermo Fischer, #4456740) and libraries were constructed with the Illumina
TruSeq Stranded mRNA sample preparation kit. Genes with fold change ±1.5
and FDR < 0.01 were considered as significantly altered. RNA-seq datasets were
processed as previously described16 (see Supplementary Methods). RNA-seq pro-
cessed for PCA and hierarchical clustering was performed with a modified version
of the in-house RNA-seq pipeline (see Supplementary Methods). Datasets were
normalised using ERCC controls before calculating logCPMs (edgeR62).
ChIP-seq assay and processing. ChIP assays were performed as previously
described17,18,63,64 for the following histone marks: H3K4me3 (Abcam, #ab8580),
H3K4me1 (Active Motif, #39297), H3K36me3 (Abcam, #ab9050), H3K27ac
(Active Motif, #39133), H2AZac (Abcam, #ab18262), H3K9ac (Millipore, #06-599)
and H3K27me3 (Millipore, #07-449). ChIP of H3K9me3 (Diagenode, #C15500003)
was performed as previously described65. We performed lamin ChIP assays in
PrEC and LNCaP as previously described66 for both Lamin B1 (Abcam, #ab16048)
and Lamin A/C (Santa Cruz, #sc7292). Each ChIP assay was validated by qPCR
against an IgG control and enrichment above input. Libraries were prepared
with the Illumina TruSeq Chip Library Prep Kit and sequenced on an Illumina
HiSeq 2500.
Sequencing data was processed as previously described17,63. Briefly, ChIP-seq
reads were aligned to hg19 using bowtie58 (v1.1.0) allowing up to 3 mismatches,
discarding ambiguous and clonal reads. All histone ChIP-seq peaks were called
using PeakRanger67 (v1.16). Broad domains of lamins (LADs), H3K9me3 and
H3K27me3 were called using the enriched domain detector (EDD) for
identification of wide genomic enrichment domains68.
DNase1 hypersensitivity assay. Cells (7 × 106 per sample) were scraped, cen-
trifuged and washed with PBS. Cell pellets were resuspended in nuclear extraction
buffer (10 mM Tris–HCl pH7.4, 12.5 mM NaCl, 3 mM MgCl, 0.1 mM EDTA, 0.5%
IGEPAL) and dounced until nuclei were visible under light microscope with 0.4%
Trypan Blue staining. DNase1 (Roche, #04716728001) was added to nuclei pellets
of LNCaP (24 U) and PrEC (12 U) and incubated at 37 °C for 15 min. DNase1
reactions were terminated by the addition of 36 mM EDTA and Proteinase K was
added before incubating at 55 °C overnight. DNA was purified by phenol-
chloroform extraction and ethanol precipitation. Samples were separated using
electrophoresis on a 1% agarose gel. 100–300 bp sections were excised and purified
using the QIAquick Gel Extraction kit. Libraries were prepared with the Illumina
TruSeq Chip Library Prep Kit and sequenced on an Illumina HiSeq 2000.
Quantification of epigenetic marks over replication timing loci. We defined
chromatin mark occupancy and methylation averages for the 1 kb wide blocks
produced in the Repli-Seq data processing. Chromatin-mark-occupied 1 kb blocks
were defined as any 1 kb block that overlapped a called ChIP-seq peak. Gain of
chromatin mark is defined as the same 1 kb block overlapping a ChIP peak in
LNCaP and not in PrEC, and the reciprocal for loss. Methylation values were
averaged over the same 1 kb blocks using the overlapMeans function within R
package aaRon (https://github.com/astatham/aaRon.git). Hypomethylation was
defined as a loss of >0.2 between PrEC and LNCaP, and hypermethylation was
defined as a gain of >0.2 between PrEC and LNCaP. For hypomethylation, we only
considered loci with methylation values of at least 0.2 in PrEC, and for hyper-
methylation, we only considered loci with methylation values below 0.8 in PrEC.
Quantification of epigenetic marks over promoters. Promoters were defined as
±1000 bp around the transcription start site from the GENCODE 19 reference
transcriptome. CpG-island promoters were defined as any promoter (2 kb) that
overlapped with a CpG-island. Early- and late-replicating genes were defined by
calculating the average WA score over the promoter. The genes with average
WA scores >75 or <20 were labelled as early and late-replicating, respectively.
Promoter-centric ChIP-seq enrichment for H3K4me3 and H3K27me3 was
calculated by counting the number of reads within the promoter region using
the Repitools R package. Fold changes (logFC) were computed as the log2 ratio
of normalised counts per promoter using the edgeR62. Methylation values were
averaged over promoter regions using the overlapMeans function within R package
aaRon (https://github.com/astatham/aaRon.git).
Genomic annotation. The CpG-islands are from Gardiner-Garden and Frommer
(1987), downloaded from UCSC69. We annotated the CpG-islands to promoters
based on overlaps to promoter regions from GENCODE 19 genes. For hypo-
methylation, we only considered CpG-islands with methylation values of at least
0.2 in PrEC, and for hypermethylation, we only considered CpG-islands with
methylation values below 0.8 in PrEC. CpG-island shores are defined as the regions
within 2 kb either side of a CpG-island. Exons and introns were called per
transcript using the GenomicFeatures70 package in R, and merged if overlapping.
Intron regions were retained if they did not intersect an exonic region. 5′ and
3′ UTRs were also called using the GenomicFeatures package, and merged if
overlapping. Intergenic regions were defined as the gaps between the other
elements.
Statistical tests. For genomic interval overlaps and genomic rearrangement
overlaps, we modified the LOLA71 package to perform a two-sided Fisher's exact
test and reports significance using ‘BH’ FDR value. Differences between percen-
tages of epigenetic elements in Early or Late timing were assessed using the two-
sample test of equal or given proportions (prop.test in R). The Student’s T-test was
used to test for significant difference between two groups of logFC values as
produced from edgeR processing. The Mann–Whitney–Wilcoxon test was used for
2-group non-parametric comparisons, and the one-tailed test was used where a
directional difference between the groups was expected. Unless otherwise stated,
statistical tests were two-sided.
Creating a randomised set of LRES and LREA domains for testing statistical
association of domains to early or late replication: Random genomic regions were
generated in a three-stage process: first, a chromosome was selected at random,
second, the start point of the region was randomly generated from a uniform
distribution between 1 and the length of the chromosome, and last, the length
of the region to be generated by sampling at random from the known lengths
of LREA or LRES regions. If the random region generated did not fit on the
chromosome, it was discarded and the process repeated. In this way, we generated
1000 regions across the genome that were distributed in length similarly to the
LREA and LRES regions. We computed the WA for each random region and
compared this empirical null distribution to the distribution of WA values for
LREA and LRES using the Mann–Whitney–Wilcoxon test. We used an exact
binomial test to examine the significance of overlap between LRES or LREA regions
and earlier or later domains. We used the proportion of randomised regions
overlapping earlier or later domains as the hypothesised probability of success
in the binomial test.
Profile plots. We used genomation72 to calculate average WA scores over regions
of interest, which were divided into 50 bins per region. We then used ggplot73
to plot the average WA scores across all regions for each bin with standard
error and confidence intervals.
Lamina boundary heatmaps. We calculated the bp distance from the PrEC LAD
5′ or 3′ boundary to the nearest LNCaP LAD 5′ or 3′ boundary, respectively.
Negative and positive distances denote that the LNCaP boundary is respectively
upstream or downstream of the PrEC boundary. Heatmaps of WA values are
centred on PrEC LAD boundaries, and are ordered by decreasing distance to
the nearest LNCaP boundary. This was performed for LADs containing both lamin
A/C and lamin B1, and LADs that overlapped between PrEC and LNCaP.
ChromHMM of heterochromatin marks and replication domains.
ChromHMM74 was used to create a 18-state model from 7 marks for PrEC and
LNCaP. The inputs were: EDD called bed files for H3K27me3, H3K9me3, lamin
A/C and lamin B1; unmethylated or ‘hypo’-methylated (HMR) bed files called by
MethPipe61; and early and late 1 kb bed files called using the cut-offs WA > 75 and
WA < 20, respectively. Binary files were created using BinarizeBed with the ‘-peaks’
option. 8–30 models were created with LearnModel using default parameters.
We chose the 18-state model as it displayed the most informative states while
maintaining a manageable number of pairwise state transitions for interpretability.
Pairwise combinations were counted per 200 bp bin (default bin size for
ChromHMM) along the genome.
Conserved replication timing alterations in cancer. WA values from all
publically available Repli-Seq datasets and our datasets were quantile-normalised
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prior to performing PCA and hierarchical clustering. PCA was performed on 1 kb
loci that were present in all datasets using the R function prcomp with default
parameters. Hierarchical clustering was performed using the hclust function in
R with the Ward’s criterion (‘ward.D2’) method. Distance matrix for clustering
was computed using the dist function in R and the Euclidean method. Cluster
groups were defined using rect.hclust from the stats package in R. Cluster boot-
strapping was performed using clusterboot from the ‘fpc’ package in R. The
same PCA and clustering was performed on PrEC, LNCaP and public RNA-seq
datasets using quantile-normalised and replicate averaged logCPM values. To
find conserved regions of changed timing in cancer (LNCaP, MCF7, SK-N-SH,
HepG2, K562, Hela S3) compared to all other Repli-Seq datasets (see Fig. 5a),
WA values were quantile-normalised and scaled before using limma75 to find
regions of difference. We filtered for regions that were significant (FDR-corrected
p < 0.05) with a logFC ≥ 1. These regions were merged if they were within 50 kb of
each other to give the final set of ECDs and LCDs. We further filtered ECDs
and LCDs through overlap with high and low replication timing variation
regions. These high/low variation regions were defined as the top and bottom
20% of 1 kb loci based on scores outputted by the ‘var’ function in R. Repli-Seq
scores per loci from all was used as input for ‘var’ to calculate a score per loci.
We further separated ECDs and LCDs into ones that associate with replication
timing of ESC. We classified a region as associated with ESC if the difference
between the averaged replication timing score of cancer to ESC was less than
0.5 for ECDs or more than −0.5 for LCDs (quantile-normalised and scaled
WA scores).
Gene set enrichment analysis for genes in ECDs and LCDs. We were unable
to call significant terms from GSEA with the stringent cutoffs initially used to
define ECD and LCDs (logFC ≥ 1, see above) due to the restricted number of
genes obtained. We relaxed our domain calling cutoff to logFC > 0 to obtain a
less stringently defined but larger list of genes for GSEA analysis. We used a
hyper-geometric test to scan the MolSigDB v6.076,77 for gene sets with statistically
significant overlap with genes found within ECDs and LCDs. More specifically,
we computed the overlap between the MolSigDB gene sets and our set of genes
and compared what would be expected by chance if equivalent number of genes
were drawn uniformly at random from the background set of genes. We report
statistically significant enrichments with Bonferroni-corrected p < 0.05.
External data. For prostate cancer breakpoints, we used the Baca et al.33, Berger
et al.34 and Robinson et al.32 datasets. Publicly available Repli-Seq datasets used in
this study were downloaded from ENCODE data portal (https://www.
encodeproject.org/matrix/?type=Experiment&assay_title=Repli-seq). These data-
sets were created by the University of Washington ENCODE group14,29. Raw
sequence data were downloaded from UCSC, mapped to hg19 and processed in the
same manner as our own Repli-Seq data as described above. Publicly available
RNA-seq datasets used in this study were downloaded from ENCODE (Supple-
mentary Table 5). HMEC and MCF7 ChIP-seq data was downloaded from
ENCODE (Supplementary Table 5). HMEC WGBS was downloaded from
GSE29127.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Code availability. All software used is published and/or in the public domain.
Custom R code is available at https://github.com/clark-lab/Replication-Timing.
Data availability
The data that support the findings of this study are available from the corre-
sponding author upon request: raw and processed. Repli-Seq and ChIP-seq data
are available from NCBI Gene Expression Omnibus (GEO) under accession
number GSE98732. RNA-seq data GEO accession number GSE73784. ChIP-seq
data GEO accession numbers GSE38685, GSE57498, GSE73785 and GSE76337.
PrEC and LNCaP WGBS data GEO accession number. Prostate cancer WGBS
GEO accession number GSE104789. A summary of the new and existing data used
in this manuscript for PrEC and LNCaP can be found in Supplementary Table 6. A
reporting summary for this article is available as a Supplementary Information file.
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